Abstract 313: Type II interleukin 1 receptor-modulated SETBP-1/SET/PP2A/p-ERK signaling reduces the therapeutic activity of regorafenib against human colorectal cancer cells
2015 ◽
2013 ◽
Vol 383
(1-2)
◽
pp. 179-189
◽
2000 ◽
Vol 185
(2)
◽
pp. 293-301
◽